{
    "clinical_study": {
        "@rank": "137679", 
        "arm_group": {
            "arm_group_label": "MK-5172", 
            "description": "Participants previously received MK-5172 as study treatment."
        }, 
        "biospec_descr": {
            "textblock": "Blood samples will be collected and retained for purposes of DNA testing and plasma will be\n      retained for future biomedical research."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This three-year multicenter study is being done to follow participants who received at least\n      one dose of MK-5172 in a previous study to determine if they remain hepatitis C virus\n      (HCV)-RNA negative over time, and to determine if they have developed antiviral resistance.\n      The study will also evaluate long-term adverse events in this population."
        }, 
        "brief_title": "Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With MK-5172 (MK-5172-017)", 
        "completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Previously participated in an MK-5172 protocol and received at least one dose of\n             MK-5172\n\n          -  Must enroll in the present study within one year of the treatment portion of the\n             previous MK-5172 protocol except in the circumstance where the previous protocol has\n             a follow-up period \u22651 year\n\n        Exclusion Criteria:\n\n          -  None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Participants who received at least one dose of MK-5172 while enrolled in a study and that\n        achieved undetectable HCV-RNA status and did not start any new HCV-RNA therapy between the\n        end of the previous study and enrollment in this study."
            }
        }, 
        "enrollment": {
            "#text": "3250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01667081", 
            "org_study_id": "5172-017", 
            "secondary_id": "2012-002232-85"
        }, 
        "intervention": {
            "arm_group_label": "MK-5172", 
            "description": "MK-5172 was not administered to participants in the course of this study.", 
            "intervention_name": "MK-5172", 
            "intervention_type": "Drug", 
            "other_name": "Participants previously received study treatment with MK-5172 at the dose and frequency specified in the study protocol."
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 7, 2014", 
        "number_of_groups": "1", 
        "official_title": "A Long-Term Follow-Up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated With MK-5172 in a Prior Clinical Trial", 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Time to Viral Relapse", 
                "safety_issue": "No", 
                "time_frame": "From Last Dose of MK-5172 Up to ~ 36 Months After Enrollment in This Study"
            }, 
            {
                "measure": "Number of Participants With Antiviral Resistance", 
                "safety_issue": "No", 
                "time_frame": "From Last Dose of MK-5172 Up to ~ 36 Months After Enrollment in This Study"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01667081"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}